What we develop
Sensorion’s mission is to offer innovative therapeutic solutions that provide long-term improvements to the lives of patients suffering from, or at risk of, inner ear disorders. In striving to fill this significant unmet medical and social need, we are continuously developing and optimizing our pipeline, mobilizing our in-house technology platform, scientific expertise, and network of experts.
| Program | Indication | Discovery | In vivo PoC | Pre-clinical | Phase 1 | Phase 2 | Phase 3 | Next milestones |
|---|---|---|---|---|---|---|---|---|
| TREAT | ||||||||
| SENS-401 SSHNL | Sudden sensorineural hearing loss | 100 | 100 | 100 | 100 | 100 | 0 | Exploring partnering options |
| PREVENT | ||||||||
| SENS-401 CIO | Cisplatin-Induced Ototoxicity | 100 | 100 | 100 | 100 | 10 | 0 | First results 1H 2023 |
| SENS-401 Cochlear | Hearing preservation after cochlear implantation | 100 | 100 | 100 | 100 | 20 | 0 | First results 1H 2023 |
| RESTORE | ||||||||
| OTOF-GT | Otoferlin deficiency | 100 | 100 | 40 | 0 | 0 | 0 | Clinical Trial Application 1H 2023 |
| GJB2-GT | GJB2 related early presbycusis | 100 | 25 | 0 | 0 | 0 | 0 | Candidate Selection 2H 2022 |
| GJB2-GT | Pediatric progressive GJB2 related hearing loss | 100 | 25 | 0 | 0 | 0 | 0 | Candidate Selection 2H 2022 |
| GJB2-GT | Congenital GJB2 related hearing loss | 100 | 25 | 0 | 0 | 0 | 0 | Candidate Selection 2H 2022 |
PRODUCTS
04 67 20 77 30
Go to the description